Medical Condition News

RSS

iCAD and AdMeTech Foundation sign a strategic partnership agreement

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a strategic partnership with the AdMeTech Foundation, a non-profit organization with a mission to end prostate cancer as a patient care crisis and socio-economic problem.

19 Nov 2009

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

Today, Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults in various European countries.

19 Nov 2009

Opiate-based painkillers can increase tumor-cell proliferation, says new study

Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.

19 Nov 2009

Sildenafil drug improves cardiac performance in young adults with congenital heart disease

Heart function significantly improved in children and young adults with single-ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children's Hospital of Philadelphia.

19 Nov 2009

Women with multiple sclerosis are less likely to have pregnancy complicaitons

There is good news for women with multiple sclerosis (MS) who are pregnant or thinking about becoming pregnant. A new study shows that pregnant women with multiple sclerosis are only slightly more likely to have cesarean deliveries and babies with a poor prenatal growth rate than women who do not have MS.

19 Nov 2009

Experimental study shows beneficial effects of Vardenafil on NSAID-induced gastric ulcer

Indomethacin has been proved by epidemiological and experimental studies to be closely associated with peptic ulcer development. Vardenafil is a potent phosphodiesterase 5 inhibitor and its effects on the gastric mucosa havenot been reported.

19 Nov 2009

Dual niacin-statin therapy improves blood cholesterol levels but does not diminish plaque buildup

The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows.

19 Nov 2009

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).

19 Nov 2009

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

BSD Medical Corporation (www.bsdmedical.com) today provided an update on the U.S. Food and Drug Administration’s (FDA) review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.

18 Nov 2009

Baby's sleep position can predict misshapen skull condition

A baby's sleep position is the best predictor of a misshapen skull condition known as deformational plagiocephaly - or the development of flat spots on an infant's head - according to findings reported by Arizona State University scientists in the December issue of the journal Pediatrics.

18 Nov 2009

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.

18 Nov 2009

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

St. Jude Medical, Inc. announced today that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.

18 Nov 2009

Key findings from AstraZeneca's phase II studies of ticagrelor

AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.

18 Nov 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Several studies have shown that lipid peroxidation stimulates collagen production in fibroblasts and hepatic stellate cells (HSC), and plays an important role in the development of liver fibrosis. Hepatoprotective effects of green tea against carbon tetrachloride, cholestasis and alcohol induced liver fibrosis were reported in many studies. However, the hepatoprotective effect of green tea in dimethylnitrosamine (DMN)-induced models has not been studied.

18 Nov 2009

Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC

Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee's Pharmaceutical Holdings, the execution of a collaboration and license agreement for Jennerex's lead product candidate, JX-594, in certain Asian territories.

18 Nov 2009

Roche Applied Science announces availability of new CIM-Plate 16 for their xCELLigence System

Roche Applied Science announces the availability of the new CIM-Plate 16 for their xCELLigence System for cell analysis, for use in cancer research. The 16-well culture plate features electronic sensors for the direct study of cell migration and invasion on the xCELLigence RTCA DP Instrument.

18 Nov 2009

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.

18 Nov 2009

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.

18 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

Medical Condition News

iCAD and AdMeTech Foundation sign a strategic partnership agreement

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

Opiate-based painkillers can increase tumor-cell proliferation, says new study

Sildenafil drug improves cardiac performance in young adults with congenital heart disease

Women with multiple sclerosis are less likely to have pregnancy complicaitons

Experimental study shows beneficial effects of Vardenafil on NSAID-induced gastric ulcer

Dual niacin-statin therapy improves blood cholesterol levels but does not diminish plaque buildup

Once-a-day dosing clinical study of udenafil for erectile dysfunction completed

Update on FDA's review of BSD-2000 Hyperthermia System for patients with cervical carcinoma provided

Baby's sleep position can predict misshapen skull condition

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

Key findings from AstraZeneca's phase II studies of ticagrelor

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC

Roche Applied Science announces availability of new CIM-Plate 16 for their xCELLigence System

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News